Crossing the Turbulent Hepatitis Sea: Use of Prophylactic Glecaprevir/Pibrentasvir to Facilitate Cardiothoracic Transplants from Hepatitis C Viremic Donors in Australia

Purpose: The availability of direct acting antivirals has enabled the acceptance of cardiothoracic organs from hepatitis C (HCV) positive donors, and this has become commonplace in the US. Issues of cost and antiviral access have delayed implementation in Australia. We aim to evaluate the first use of compassionate access prophylactic glecaprevir/pibrentasvir to prevent HCV infection in cardiothoracic transplant recipients receiving organs from viraemic donors in a single Australian center.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Source Type: research